In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

CytRx Corp.. Trade Record

NASDAQ:CYTR CytRx Corp. stock gains 6.58% Exit Apr 20, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CYTR Apr 19, 2017, priceSeries
About CytRx Corp.

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
89.02
Entry Date
Apr 19, 2017
Entry Price
3.12
Sell Date
Apr 20, 2017
Sell Price
3.33
Net Gain
6.58%
Hold Time
1 Trading Days